Scarica l'app Stockscreener
10.02
2.15%
-0.23
Precedente Chiudi:
$10.25
Aprire:
$10.15
Volume 24 ore:
40,516
Relative Volume:
0.25
Capitalizzazione di mercato:
$144.79M
Reddito:
$166.88M
Utile/perdita netta:
$-74.18M
Rapporto P/E:
-1.9763
EPS:
-5.07
Flusso di cassa netto:
$1.14M
1 W Prestazione:
-2.62%
1M Prestazione:
+6.59%
6M Prestazione:
+15.02%
1 anno Prestazione:
-43.04%
Intervallo 1D:
$10.04
$10.31
Intervallo di 1 settimana:
$10.03
$10.62
Portata 52W:
$7.8701
$18.34
Anika Therapeutics Inc Stock (ANIK) Company Profile
Nome
Anika Therapeutics Inc
Settore
Telefono
(781) 457-9000
Indirizzo
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
10.04 | 147.82M | 166.88M | -74.18M | 1.14M | -5.07 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.33 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.38 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.18 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.95 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.82 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | B. Riley Securities | Buy |
| 2024-11-01 | Reiterato | Barrington Research | Outperform |
| 2023-08-14 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | Ripresa | Stephens | Equal-Weight |
| 2022-03-09 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | Iniziato | Stephens | Overweight |
| 2021-07-16 | Iniziato | UBS | Neutral |
| 2020-12-16 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | Aggiornamento | Sidoti | Neutral → Buy |
| 2020-01-10 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | Iniziato | BWS Financial | Sell |
| 2019-09-24 | Reiterato | Barrington Research | Outperform |
| 2019-09-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | Aggiornamento | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | Downgrade | Sidoti | Buy → Neutral |
| 2018-07-27 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | Reiterato | Barrington Research | Outperform |
| 2016-05-09 | Aggiornamento | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | Reiterato | Barrington Research | Outperform |
Mostra tutto
Anika Therapeutics Inc Borsa (ANIK) Ultime notizie
(ANIK) Volatility Zones as Tactical Triggers - Stock Traders Daily
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Positive week for Anika Therapeutics, Inc. (NASDAQ:ANIK) institutional investors who lost 41% over the past year - simplywall.st
Lumicell Appoints Biotech and Medtech Leader Cheryl R. Blanchard, Ph.D., to Board of Directors - ChartMill
Anika Therapeutics Inc. (NASDAQ:ANIK) Short Interest Update - MarketBeat
Anika Therapeutics Inc. $ANIK Shares Acquired by Capital Management Corp VA - MarketBeat
Price-Driven Insight from (ANIK) for Rule-Based Strategy - Stock Traders Daily
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc. - ACCESS Newswire
United States Joint Pain Injection Market to hit US$ 4.05 Billion - openPR.com
Anika Therapeutics Faces Investor Lawsuit Over Securities Violations - Intellectia AI
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders - GlobeNewswire Inc.
Anika Therapeutics Shares Plunge 27% After Clinical Trial Fails to Meet Primary Endpoints - Intellectia AI
ANIK Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc. - marketscreener.com
Aug Weekly: Is COFPRL being accumulated by smart moneyJuly 2025 Market Mood & Fast Gain Stock Tips - baoquankhu1.vn
(ANIK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Can Anika Therapeutics Inc. stock withstand economic slowdownJuly 2025 Action & Growth Oriented Trade Recommendations - bollywoodhelpline.com
How Anika Therapeutics Inc. stock performs in rising dollar environmentFed Meeting & Smart Allocation Stock Tips - Bollywood Helpline
Anika Therapeutics Builds Focused Platform For Joint Health Care - Kalkine Media
Will Anika Therapeutics Inc. stock benefit from infrastructure spendingMarket Risk Report & Long Hold Capital Preservation Plans - ulpravda.ru
Anika Therapeutics (NASDAQ:ANIK) Given “Outperform” Rating at Barrington Research - Defense World
(ANIK) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Barrington Research Reiterates Outperform Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Anika Therapeutics (ANIK): Barrington Research Maintains Outperf - GuruFocus
Anika Therapeutics names Stephen Griffin as new CEO - Investing.com
Is Anika Therapeutics Inc. stock trading near support levels2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
Anika Therapeutics Announces CEO Transition and Governance Changes - TipRanks
Will Anika Therapeutics Inc. (AKP) stock see insider accumulationMarket Sentiment Report & Growth Focused Stock Pick Reports - Улправда
Anika Therapeutics Announces Leadership Transition - Ortho Spine News
Is Anika Therapeutics Inc. (AKP) stock inflation resilientJuly 2025 PreEarnings & Growth Oriented Trade Recommendations - Улправда
How Anika Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Review & Expert Verified Stock Movement Alerts - Улправда
Anika Therapeutics, Inc. Announces Chief Executive Officer Changes - MarketScreener
Anika Therapeutics names Stephen Griffin as new CEO By Investing.com - Investing.com Australia
Cosmetic Surgery Market Is Booming Worldwide 2025-2032 | - openPR.com
Anika Therapeutics Shares Plunge 27.42% After Clinical Trial Results Fail to Meet Primary Endpoints - Intellectia AI
How Low Can Anika Therapeutics Stock Really Go? - Trefis
Why Anika Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Community Trade Idea Sharing - Улправда
Market Pulse: Why Anika Therapeutics Inc. stock is trending among retail tradersDip Buying & Daily Technical Forecast Reports - Улправда
Is Anika Therapeutics Inc. stock attractive for retirement portfolios2025 AllTime Highs & Low Risk Entry Point Guides - DonanımHaber
Why Anika Therapeutics Inc. stock could see breakout soonWeekly Investment Recap & Capital Protection Trading Alerts - DonanımHaber
Regenerative Medicine (Bone and Joint) Market Is Going to Boom | Anika Therapeutics, Inc, Arthrex, Inc. - openPR.com
Why Anika Therapeutics Inc. stock is trending among retail tradersQuarterly Profit Review & Expert Curated Trade Setup Alerts - Улправда
(ANIK) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Income Plays: Why Anika Therapeutics Inc. stock is trending among retail tradersJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
Anika Therapeutics’ Earnings Call: Growth Amid Challenges - MSN
Is the Options Market Predicting a Spike in Anika Therapeutics Stock? - sharewise.com
Is Anika Therapeutics Inc a good long term investmentTechnical Analysis Insights & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Europe Viscosupplementation Market Detailed In New Research - openPR.com
Responsive Playbooks and the ANIK Inflection - Stock Traders Daily
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP - GlobeNewswire
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 2025CEO Change & Weekly Return Optimization Alerts - Newser
Anika Therapeutics Inc Azioni (ANIK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anika Therapeutics Inc Azioni (ANIK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
0.39%
8.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):